MO Strengthens on! Brand: Can it Sustain Momentum in Nicotine Pouches?

Altria (MO) reported strong Q1 2025 performance for its 'on!' nicotine pouch brand, with shipments growing over 18% and its segment share reaching 17.9%, fueled by strategic marketing efforts like the 'It's On!' campaign and the upcoming launch of 'on! PLUS'. Despite intense competition from Philip Morris's ZYN and Turning Point Brands, Altria's disciplined strategy and growing brand equity are sustaining momentum in the expanding smoke-free category, with MO shares outperforming the industry and trading at a forward P/E of 10.84x, below the industry average.

Analysis

Altria (MO) is demonstrating significant progress in its strategic shift towards the smoke-free category, driven by the robust performance of its 'on!' nicotine pouch brand. In the first quarter of 2025, 'on!' shipments grew by over 18%, increasing its share of the oral tobacco market to 8.8% and its share within the specific nicotine pouch segment to 17.9%. This growth is underpinned by an aggressive marketing strategy, exemplified by the 'It's On!' campaign which boosted consumer impressions fivefold and raised brand awareness to over 60%. The planned launch of 'on! PLUS' signals a continued focus on product innovation to capture new demographics. While Altria is gaining ground, the competitive environment is intense. Philip Morris's (PM) ZYN brand remains the dominant force, with shipment growth of 63% in Q1, and is actively working to resolve supply constraints. Meanwhile, smaller competitors like Turning Point Brands (TPB) are also achieving nearly tenfold year-over-year revenue growth in the category. Financially, Altria's stock has shown relative strength, gaining 1.5% in the past month against a 0.2% industry decline. Its valuation appears attractive, with a forward P/E ratio of 10.84x, well below the industry average of 15.11x, while consensus estimates project earnings growth of 4.9% for 2025.

Key Decisions for Investors

• Given Altria's successful execution in the high-growth nicotine pouch segment, its relative stock outperformance, and a forward P/E multiple that is at a discount to the industry, investors could consider the stock a compelling value play on the transition to smoke-free products.
• Investors should closely monitor competitive dynamics, particularly Philip Morris's progress in resolving ZYN's supply issues, as increased availability of the market-leading product could intensify pressure on Altria's market share gains.
• The upcoming launch and market adoption of the 'on! PLUS' variant should be viewed as a key catalyst and a test of Altria's ability to innovate and expand its user base within the competitive oral nicotine space.